Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from 3SBio ( (HK:1530) ) is now available.
3SBio Inc. has proposed a final ordinary cash dividend of HKD 0.25 per share for the financial year ended 31 December 2025, underscoring its intention to return cash to shareholders. The dividend, subject to shareholder approval on 25 June 2026, will go ex-dividend on 21 July 2026, with a record date of 27 July 2026 and payment scheduled for 4 August 2026, providing clarity on the income timeline for investors.
The announcement signals continued confidence by the board in the company’s financial performance and cash generation capacity, which may support its positioning as a yield-oriented healthcare stock in the Hong Kong market. The board comprises a mix of executive, non-executive and independent non-executive directors, suggesting a standard corporate governance structure that may reassure institutional and retail stakeholders focused on oversight and dividend policy stability.
The most recent analyst rating on (HK:1530) stock is a Hold with a HK$25.00 price target. To see the full list of analyst forecasts on 3SBio stock, see the HK:1530 Stock Forecast page.
More about 3SBio
3SBio Inc. is a biopharmaceutical company listed in Hong Kong under stock code 01530. It focuses on developing, manufacturing and marketing pharmaceutical products, with its shares traded on the Main Board of the Hong Kong Stock Exchange, targeting investors seeking exposure to the healthcare sector.
YTD Price Performance: -0.83%
Average Trading Volume: 23,046,124
Technical Sentiment Signal: Buy
Current Market Cap: HK$60.86B
Learn more about 1530 stock on TipRanks’ Stock Analysis page.